SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Integris Medtech Ltd

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Trading | | Integris Medtech Share Price

BSE Share Price
Not Listed

Integris Medtech Ltd

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Trading | | Integris Medtech Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
-
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
3.81%
Return on Capital Employed (ROCE)
4.06%
Return on Assets (ROA)
3.41%
Operating Profit Margin
-17.3%
Net Profit Margin
92.44%
Gross Profit Margin
107%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-34.25%
Operating Profit Growth (1 Year)
-
-1169.35%
Net Profit Growth (1 Year)
-
16.62%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
-
Face Value
-
All Time Low / High
- / -

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Mar'23Mar'24Mar'25TTM
ROCE % 3.4%5.9%4.1%-

Growth Parameters

Sales 62.758.338.30
Sales YoY Gr.--7%-34.3%-
Adj EPS 4.26.56.40
YoY Gr.-56.5%-2.9%-
BVPS (₹) 126.6132.7202.50
Adj Net
Profit
2132.837.5NAN
Cash Flow from Ops. 6.7-13.8-66.1-
Debt/CF from Ops. 2.3-6.2-0-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANA-34.3%
Adj EPS NANANA-2.9%
BVPSNANANA52.6%
Share Price - - - -

Key Financial Parameters

Mar'23Mar'24Mar'25TTM
Return on
Equity %
3.34.83.90
Op. Profit
Mgn %
1.51.7-17.3NAN
Net Profit
Mgn %
33.456.297.7NAN
Debt to
Equity
00.10-
Working Cap
Days
05591,2550
Cash Conv.
Cycle
0-126940

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales62.7058.3138.34
Operating Expenses + 61.7457.6944.97
Manufacturing Costs0.020.020.05
Material Costs57.7654.6835.30
Employee Cost 0.440.223.46
Other Costs 3.532.776.17
Operating Profit 0.960.62-6.63
Operating Profit Margin (%) 1.5%1.1%-17.3%
Other Income + 23.6345.8052.57
Exceptional Items -2.64-3.02-4.58
Interest 0.239.350.99
Depreciation 0.100.100.14
Profit Before Tax 21.6233.9440.23
Tax 1.603.554.79
Profit After Tax 20.0230.3935.44
PAT Margin (%) 31.9%52.1%92.4%
Adjusted EPS (₹)4.06.16.0
Dividend Payout Ratio (%)0%0%0%

Valuation of Integris Medtech - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 634.52728.381,194.35
Share Capital 1.6765.141.97
Reserves 632.85663.241,192.39
Debt +15.1385.720.69
Long Term Debt083.530
Short Term Debt15.132.190.69
Minority Interest000
Trade Payables44.2117.873.74
Others Liabilities 1.735.3444.05
Total Liabilities 695.59837.311,242.83

Fixed Assets

Net Fixed Assets +0.380.420.98
Gross Block0.720.861.56
Accumulated Depreciation0.330.440.58
CWIP 000
Investments 574.29678.21845.18
Inventories1.910.692.55
Trade Receivables20.6710.6529.87
Cash Equivalents 10.8144.89221.68
Others Assets 87.52102.46142.57
Total Assets 695.59837.311,242.83

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity + 6.68-13.76-66.07
PBT 21.6233.9440.23
Adjustment -18.75-34.15-45.25
Changes in Working Capital 5.59-11.07-58.08
Tax Paid -1.78-2.49-2.97
Cash Flow From Investing Activity + -17.47-120.05-276.36
Capex 00-0.24
Net Investments -1.94-149.56-486.69
Others -15.5329.50210.57
Cash Flow From Financing Activity + 15125.13352.19
Net Proceeds from Shares 00358.28
Net Proceeds from Borrowing 000
Interest Paid -0.08-0.53-0.18
Dividend Paid 000
Others 15.08125.66-5.91
Net Cash Flow 4.20-8.699.77

Financial Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)3.164.683.81
ROCE (%)3.365.924.06
Asset Turnover Ratio0.110.10.04
PAT to CFO Conversion(x)0.33-0.45-1.86
Working Capital Days
Receivable Days103.2078.20176
Inventory Days9.506.5014.10
Payable Days279.40207.20111.70

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Integris Medtech Ltd FAQs

The current trading price of Integris Medtech on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Integris Medtech stood at ₹0.00 Cr

The latest P/E ratio of Integris Medtech as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Integris Medtech as of 31-Dec-1969 is 0.00.

The 52-week high of Integris Medtech is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Integris Medtech is ₹0.00 ( Cr.) .

Data is not available for this company.

No data found

No data found

About Integris Medtech Ltd

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×